Speaker:  Dr. Jose Antonio Seoane Fernández, coordinates the Cancer Computational Biology group at VHIO. Originally trained as a computer scientist, he transitioned to cancer genomics and epigenetics during his postdoctoral research at the Christina Curtis lab at Stanford University. In 2021, after securing a Ramon y Cajal grant, he establish his laboratory at VHIO. The primary focus of the lab is to identify biomarkers of drug response in solid tumors, elucidate the role of epigenetics in cancer initiation, progression and metastasis, and investigate the potential of chromatin machinery genes as therapeutic targets, using computational tools.

Abstract:
Many genomic signatures have been developed, but most of them never arrive to the clinic. Out hypothesis is that most of the signatures developed are actually giving the same message. Here we developed a transcriptomic based signature for colon cancer prognosis. Out signature is able to match other colorectal prognostic signatures, and on top on that, is able to predict response to a specific chemotherapy. We have validated our signature in in-silico cell line response databases, and also in colorectal patient derived organoids.